Search the Newsreel

Regional Management Corp. (RM) CEO purchases 10,000 shares in open market trades

Regional Management Corp. CEO Lakhbir S. Lamba purchased 10,000 shares of the company's common stock in open market transactions on August 11-12, 2026. The purchases were executed at weighted average prices in the low $30s per share. This insider buying demonstrates a positive sentiment, …

Regency Centers Corp. stock outperforms competitors on strong trading day

Regency Centers Corp. (REG) stock rose 1.48% on Thursday, closing at $76.86, outperforming the broader market which also saw gains with the S&P 500 and Dow Jones Industrial Average rising. This gain ended a three-day losing streak for the company's shares.

Here’s How Much You Would Have Made Owning Regions Financial Stock In The Last 15 Years

Regions Financial (NYSE: RF) has outperformed the market over the past 15 years, achieving an average annual return of 15.06%. An initial investment of $1000 in RF stock 15 years ago would now be worth $7,556.09, demonstrating the significant impact of compounded returns. The …

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Regeneron Pharmaceuticals Inc. (REGN) saw its stock price rally by 1.00% to $805.97, outperforming its competitors and the broader market on a strong trading day. This marked the stock's second consecutive day of gains, with the S&P 500 Index and Dow Jones Industrial Average …

Fed Bars Former Regions Bank Employee Over Check Fraud

The Federal Reserve Board has permanently barred former Regions Bank employee Elazia Jones from the banking industry for her role in a check-fraud scheme. Jones allegedly knowingly cashed counterfeit checks, contributing to over $396,000 in losses for Regions Bank. While Jones consented to the …

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

A class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, leading to …

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is reminding investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN) for alleged securities fraud. The lawsuit claims Regeneron made false and misleading statements regarding its Phase III Fianlimab-Libtayo Study, which supposedly failed to demonstrate clinical differentiation. Investors …

Regent Pacific Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend

Are Wall Street Analysts Bullish on Regency Centers Stock?

FEDERATED HERMES, INC.'s Regions Financial Corp(RF) Holding History

This article details FEDERATED HERMES, INC.'s historical holdings in Regions Financial Corp (RF). As of June 30, 2026, FEDERATED HERMES, INC. held 11.17 million shares of RF, valued at $337.47 million, representing 0.49% of their portfolio. The firm has an estimated gain of $125.66 …

Region Group (RGN) Stock Forum and Discussion

Telix Pharmaceuticals (ASX:TLX) Posts US$247M Quarter and Targets Over US$1B 2026 Revenue Plus Other Income

Telix Pharmaceuticals reported its strongest quarterly revenue to date, reaching US$247 million in Q2 2026, driven by its Precision Medicine division. The company projects its total 2026 revenue plus other income to exceed US$1 billion, bolstered by a US$40 million payment from a new …

Regions Financial Makes New Executive Leadership Appointments Following Planned Retirement of Keenan

Regions Financial is making executive leadership changes following the planned retirement of Chief Administrative Officer Dave Keenan at the end of 2026. Kate Danella will succeed Keenan as Chief Administrative Officer, while John Jordan will take over Danella's previous role as Head of Consumer …

Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $640,000.00 in Stock

Regeneron Pharmaceuticals director Huda Zoghbi sold 800 shares of the company's stock for $640,000, reducing her direct ownership by nearly 32%. This transaction occurred under a pre-arranged Rule 10b5-1 trading plan. The sale comes as Regeneron reported strong quarterly earnings with revenue up 16.7% …

Regal Rexnord (RRX) Orders Are Surging, So Why Is Margin Guidance Falling?

Regal Rexnord (NYSE:RRX) just posted its strongest order growth in years in its August 5 earnings release, with a new chief executive at the helm as of July 1. Yet in the same breath, management trimmed its full-year profitability outlook. That contradiction, momentum on …

Northern Region Cement Company Reports Earnings Results for the Second Quarter Ended June 30, 2026

REGN Stockholders May Be Entitled to Lead the Class Action Lawsuit Against Regeneron Pharmaceuticals, Inc. - Contact Robbins LLP for Information About Becoming the Lead Plaintiff

Robbins LLP is reminding investors who purchased Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025, and May 15, 2026, about a securities class action lawsuit. The lawsuit alleges that Regeneron misled investors regarding its Phase 3 Fianlimab-Libtayo clinical trial for advanced melanoma, …

Technical Reactions to RM Trends in Macro Strategies

This article analyzes Regional Management Corp. (NYSE: RM) using AI models, identifying weak near- and mid-term sentiment but a neutral long-term outlook. It presents three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored to different risk profiles, highlighting an exceptional 52.6:1 risk-reward setup. …

Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP

Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals (NASDAQ: REGN) on behalf of investors who suffered substantial losses. The lawsuit stems from surprising revelations about a failed Phase 3 clinical trial for a melanoma therapy, which caused …

(RGNX) as a Liquidity Pulse for Institutional Tactics

This article provides an AI-driven analysis of Regenxbio Inc. (NASDAQ: RGNX), highlighting mixed sentiment and a mid-channel oscillation pattern. It outlines institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss levels. The analysis also includes a …

Precision Trading with Regency Centers Corporation (REG) Risk Zones

This article provides a detailed analysis of Regency Centers Corporation (REG) using AI models, highlighting its weak near and mid-term sentiment but a positive long-term outlook. It outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses. The …

Is Regency Worth Buying as Leasing Strength Meets Development Risk?

Regency Centers Corporation (REG) is balancing strong leasing performance and development opportunities with potential risks from higher financing costs and geographic concentration. While the company's high occupancy rates and healthy rent growth support its earnings, a significant development pipeline and debt load introduce execution …

Regency Raises 2026 Outlook as Leasing Momentum Builds Into Year-End

Regency Centers Corporation (REG) has increased its 2026 outlook following strong second-quarter performance in leasing, occupancy, and same-property net operating income. The company's raised guidance reflects better operating trends, a substantial signed-not-occupied pipeline providing future rent visibility, and healthy rent spreads indicating continued pricing …

Regions Bank names next chief administrative officer

Regions Bank has appointed Kate Danella, currently head of consumer banking, as its next chief administrative officer, succeeding Dave Keenan who will retire at the end of the year. Danella will oversee strategic planning, digital banking, community engagement, and platform modernization. This change, along …

REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE

Bernstein Liebhard LLP reminds investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) with losses that they have until September 14, 2026, to join a securities class action lawsuit. The lawsuit alleges that Regeneron made false and misleading statements between August 1, 2025, and May 15, …

Regeneron Pharmaceuticals, Inc. Notice of September 14,

Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals (NASDAQ: REGN) on behalf of investors who purchased shares between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made misleading statements regarding a failed Phase …

Better Value & Growth: INCY, HALO Top Regeneron Pharmaceuticals Stock

Regal Hotels Sets Board Meeting to Approve Interim Results

Insight Wealth Strategies LLC Has $5.46 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Insight Wealth Strategies LLC increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 26.9% in the second quarter, bringing its total holdings to $5.46 million. Regeneron reported strong quarterly results with significant revenue growth and beat EPS estimates, maintaining a "Moderate Buy" consensus rating from …

Regeneron, Tenet leads top healthcare companies with highest earnings beats (XLV:NYSEARCA)

Regeneron Pharmaceuticals and Tenet Healthcare lead the healthcare sector with the highest positive earnings per share surprises, according to an analysis of corporate earnings. Other companies with significant beats include Eli Lilly, Biogen, and UnitedHealth. While positive EPS surprises indicate operational resilience and exceeding …

Regis Healthcare (ASX:REG) Shares Retreat — Is Australia's Ageing Population Still the Ultimate Long-Term Tailwind?

How Regeneron Pharmaceuticals Went From Cheaper Than Incyte To The Pricier Stock

Regeneron Pharmaceuticals (REGN) now trades at a premium compared to Incyte (INCY), a reversal from a year ago. Regeneron's premium is attributed to its scale, blockbuster drugs like Dupixent and EYLEA HD, and a deep pipeline of approximately 50 clinical programs, despite slower growth …

Regencell Bioscience Holdings Ltd (RGC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Handelsbanken Fonder AB Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Handelsbanken Fonder AB significantly reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 58.1% in the second quarter, selling 72,708 shares and leaving them with 52,328 shares valued at $32,629,000. This move comes as other institutional investors have both increased and decreased their holdings in …

Fulton Bank N.A. Takes $1.81 Million Position in Regions Financial Corporation $RF

Fulton Bank N.A. has acquired a significant position in Regions Financial Corporation, purchasing 59,789 shares valued at approximately $1.81 million in the second quarter. Regions Financial exceeded its quarterly earnings and revenue expectations, reporting $0.68 EPS and $1.95 billion in revenue, and subsequently increased …

Regions Financial Corp (MIL:1RFU) Stock Price, Trades & News

This GuruFocus page provides a detailed overview of Regions Financial Corp (MIL:1RFU), including its current stock price, key financial metrics like P/E and P/B ratios, market capitalization, and various financial strength, growth, momentum, and profitability ranks. It also offers insights into its business description, …